However, targeting, for example, the RIPK1 pathway with GSK2982772 in rheumatoid arthritis showed decrease production of MMP3 compared with the placebo group (40) and may be a potential avenue for treatment in cGVHD. Here, RIPK1 is linked to rheumatoid arthritis.